UNSPSC 51361909: Butalbital

This classification denotes a barbiturate with the molecular formula C11H16N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KHS0AZ4JVK, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-methylpropyl)-5-(2-propenyl)- but generally known as butalbital, which bears US NIH Compound Identifier 2481. Butalbital most often comes in base and sodium forms. European Medicines Agency schedules Butalbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05999MIG.

UNSPSC 51361909 Butalbital is a Commodity code that nominally describes a barbiturate pharmaceutical, but the recent state and local opportunities tagged under it reflect a much broader procurement reality: state and local health agencies are sourcing generic pharmaceuticals, over-the-counter products, and drug-response systems through cooperative purchasing agreements and direct county health initiatives. The scope of work includes manufacturing and distribution of generic multi-source pharmaceuticals and OTC products to state and local healthcare facilities, naloxone and drug deactivation systems for community health support, and direct-to-manufacturer prescription fulfillment capacity. Issuing bodies span state health and human services departments (Texas HHS Commission), state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota and Oregon), and county health departments (Seminole County, Florida). These jurisdictions use both formal RFPs with multi-vendor awards and exploratory RFIs to shape procurement strategy before committing to formal solicitations.

Geographic activity centers on Texas, Minnesota, and Florida based on recent postings. The Minnesota MMCAP RFP issued January 20, 2026, with a March 26, 2026 response deadline, seeks manufacturers of generic pharmaceuticals and OTC products for distribution through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) to state and local facilities across Minnesota and Oregon, with awards effective July 1, 2026 and contract terms of two years with optional extensions. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription programs and direct contracting capacity outside traditional pharmacy benefit manager and group purchasing organization channels, signaling the state's intent to reshape its pharmacy procurement model. Vendors pursuing this code should expect manufacturer certification requirements (cGMP, DSCSA compliance), multi-wholesaler distribution relationships, and competitive pricing evaluation weighted heavily against administrative and compliance criteria.